Ready to get started?
Tirzepatide
Dual GIP/GLP-1 receptor agonist for medically supervised weight loss. The newest generation of weight loss medication targeting two hormones for potentially enhanced results up to 22% body weight reduction.
Ready to get started?
Dual GIP/GLP-1 receptor agonist for medically supervised weight loss. The newest generation of weight loss medication targeting two hormones for potentially enhanced results up to 22% body weight reduction.
Tirzepatide is the newest generation of prescription weight loss medication, representing a significant advancement in medical weight management. Marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, this medication is a dual GIP/GLP-1 receptor agonist that targets two key hormone pathways involved in appetite regulation and metabolism.
By activating both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, Tirzepatide provides enhanced weight loss potential compared to single-pathway medications. Clinical trials have demonstrated remarkable results, with patients achieving up to 22% body weight reduction when combined with lifestyle modifications and medical supervision.
Clinical trials demonstrate up to 22% body weight reduction, potentially exceeding results seen with single-pathway GLP-1 medications.
Targets both GIP and GLP-1 receptors for comprehensive metabolic benefits, working on two pathways that regulate appetite and blood sugar.
Significant improvements in blood sugar control, cholesterol levels, blood pressure, and other metabolic health indicators.
Studies suggest cardiovascular protective effects, including reduced risk of heart-related events in patients with obesity.
Self-administered injection provides effective treatment with minimal disruption to your daily routine.
Represents the newest advancement in weight loss medication, offering state-of-the-art treatment backed by rigorous clinical research.
Tirzepatide for weight loss is appropriate for adults who meet specific criteria and are committed to achieving maximum weight loss potential through a comprehensive program. The best candidates include:
Adults with BMI of 30 or higher (obesity)
Adults with BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol)
Those seeking potentially greater weight loss than other medications offer
Committed to making comprehensive dietary and lifestyle changes
No personal or family history of medullary thyroid cancer or MEN 2
No history of pancreatitis
No contraindications to GLP-1/GIP medications
Not pregnant, planning pregnancy, or breastfeeding
Tirzepatide is a dual-action medication that targets both GLP-1 and GIP receptors. This dual mechanism provides enhanced weight loss results, with clinical trials showing weight loss of up to 22%. It reduces appetite, slows stomach emptying, and improves metabolic health.
Tirzepatide activates two hormone pathways: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 reduces appetite and slows stomach emptying. GIP enhances insulin release and may provide additional metabolic benefits. Together, these pathways work synergistically to reduce hunger, increase satiety, and improve metabolic health.
Tirzepatide is ideal for patients seeking maximum weight loss potential, those with a BMI of 30+ or 27+ with weight-related conditions, or patients with type 2 diabetes who could benefit from the dual-action glucose control. During your consultation, your provider will help determine if Tirzepatide is best suited for your specific health profile and weight loss goals.
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These are similar to other GLP-1 medications and usually improve over time as your body adjusts. Starting with a low dose and gradually increasing helps minimize these effects. We'll monitor your progress and can adjust your treatment plan if needed.
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) has been FDA-approved since 2023. While supply has varied since its introduction, availability continues to improve. During your consultation, we'll discuss current availability and help you understand your options for obtaining this medication.
Yes, patients can often switch from other GLP-1 medications to Tirzepatide. The transition protocol depends on your current dose and response. Your provider will evaluate your treatment history and create a safe switching plan if Tirzepatide is appropriate for you.